Shubh G: NeoCOAST and AEGEAN trial results at WCLC

Shubh G, VP, US Franchise Head, Immuno-Oncology and GI Tumors at AstraZeneca, shared a post on LinkedIn:

“This content is for US audiences only.

Our momentum in IO is accelerating here in San Diego at the World Conference on Lung Cancer. With new studies on the potential impacts of our IO treatments, we’re setting the pace for what’s possible in lung cancer:

At a Presidential Symposium, we shared the results from the NeoCOAST Phase II platform trial of our IO medicine in multiple novel combinations, before and after surgery, in early resectable NSCLC, building on the backbone with the AEGEAN study. The trial arm of neoadjuvant IO plus TROP-2-directed antibody drug conjugate (ADC) plus chemo demonstrated higher pathological complete response (PCR) rate and major pathological response (mPR) than other combination regimens. The NeoCOAST data provide additional evidence that we should focus on the critical nuances among patients depending on their resectability status. With combination therapies delivered as perioperative treatment, we hope to help patients better manage their lung cancer in the earlier stages and ultimately improve their health outcomes.

Only a few weeks have passed since the FDA approved the AEGEAN regimen for perioperative treatment in early-stage resectable non-small cell lung cancer (NSCLC). Today, we reported additional event free survival, disease-free survival and overall survival results from a second planned interim analysis. The updated results reaffirm the perioperative approach for resectable NSCLC, supporting continued use of our IO treatment with chemo as a safe and efficacious option for this patient population.

At ASCO, the ADRIATIC Phase III trial made headlines as the first major advancement in limited-stage small cell lung cancer (LS-SCLC) in decades, with meaningful improvements in overall survival and progression-free survival. The patient-reported outcomes from ADRIATIC build on our success with the PACIFIC regimen, validating the impact of IO therapy in conjunction with cCRT.

We are committed to Every Patient Every Stage and we continue to push our IO innovations as far as science will allow us to go. After this year’s WCLC24, we believe the next wave of IO breakthroughs is within reach for thousands of patients – with renewed hope for better outcomes and ultimately, longer survival.

We’re headed straight from WCLC to the European Society of Medical Oncology (ESMO24) in just a few days, energized by the opportunity to rewrite the future of lung cancer care. Stay tuned for more updates.”

Source: Shubh G./LinkedIn